0
Skip to Content
Autonomous Therapeutics, Inc.
Home
Team
Media
Careers
Contact
FCOI
Autonomous Therapeutics, Inc.
Home
Team
Media
Careers
Contact
FCOI
Home
Team
Media
Careers
Contact
FCOI
Featured
Autonomous Therapeutics and Mink Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
November 3, 2024
Autonomous Therapeutics and Mink Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
November 3, 2024
Read more →
November 3, 2024
Autonomous CEO, Dr. Ariel Weinberger, serves on keynote panel at World Vaccine & Immunotherapy Congress
November 3, 2024
Autonomous CEO, Dr. Ariel Weinberger, serves on keynote panel at World Vaccine & Immunotherapy Congress
November 3, 2024
Read more →
November 3, 2024
Autonomous CEO, Dr. Ariel Weinberger, gives plenary presentation at NIH Synthetic Biology Consortium Meeting
November 3, 2024
Autonomous CEO, Dr. Ariel Weinberger, gives plenary presentation at NIH Synthetic Biology Consortium Meeting
November 3, 2024
Read more →
November 3, 2024
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
November 3, 2024
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
November 3, 2024
Read more →
November 3, 2024
Keynote Panel @ RNA Leaders USA Congress
September 19, 2023
Keynote Panel @ RNA Leaders USA Congress
September 19, 2023
Read more →
September 19, 2023
Op-Ed in BioCentury: The urgent need for variant-proof therapeutics
April 15, 2023
Op-Ed in BioCentury: The urgent need for variant-proof therapeutics
April 15, 2023

Warp speed isn’t fast enough: the need for variant-proof therapeutics

Broad-spectrum vaccines and therapies are needed to get ahead of the next pandemic, and stay ahead of viral variants

Read more →
April 15, 2023
Autonomous Therapeutics, CEO, Dr. Ariel Weinberger, interviewed by Vaccine Nation about next-generation mRNA therapeutics and antivirals
April 15, 2023
Autonomous Therapeutics, CEO, Dr. Ariel Weinberger, interviewed by Vaccine Nation about next-generation mRNA therapeutics and antivirals
April 15, 2023

Autonomous Therapeutics CEO, Ariel Weinberger, is a keynote panelist on pandemic preparedness at World Vaccine and Immunotherapy Conference / World Antiviral Congress

Read more →
April 15, 2023
Autonomous CEO, Dr. Ariel Weinberger, presents on novel mRNA therapeutic technologies at the World Antiviral Congress
November 21, 2021
Autonomous CEO, Dr. Ariel Weinberger, presents on novel mRNA therapeutic technologies at the World Antiviral Congress
November 21, 2021

Autonomous Therapeutics CEO, Ariel Weinberger, is a keynote panelist on pandemic preparedness at World Vaccine and Immunotherapy Conference / World Antiviral Congress

Read more →
November 21, 2021
BioBuzz Interviews Autonomous Therapeutics CEO Ariel Weinberger
January 19, 2021
BioBuzz Interviews Autonomous Therapeutics CEO Ariel Weinberger
January 19, 2021

“Rockville, Maryland’s Autonomous Therapeutics (Autonomous) is a rapidly expanding biotech developing the next generation of antivirals and therapeutics. Founded four years ago in New York City by University of Maryland alum and Harvard-trained scientist, Ariel Weinberger, the company has expanded into an 18,000 square foot facility in Rockville […}”

Read more →
January 19, 2021
Antiviral drug company working on Covid-19 relocates to Rockville
October 19, 2020
Antiviral drug company working on Covid-19 relocates to Rockville
October 19, 2020

“A New York City antiviral drug company that’s working on therapeutics for Covid-19 and other respiratory viruses is moving its headquarters to Rockville. Autonomous Therapeutics Inc. CEO Dr. Ariel Weinberger said Thursday the company is making the move to be closer to agencies such as the National Institutes of Health, Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA) — as well as funders. The company signed a lease for 17,700 square feet at 1530 E. Jefferson St., just off Rockville Pike. Terms were not disclosed.”

Read more →
October 19, 2020